Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
5-mg Desloratadine · 2 trials · 3 indications
AM/PM PRIOR (the participant's status over previous 12 hours) T5SS from the participant's daily diary averaged over treatment Days 1 to 29. AM/PM is the average of separate morning (AM) and evening (PM) evaluations. Scores were defined for T5SS as 0: no symptoms to 15: all severe symptoms. A two-way analysis of variance (ANOVA) model with treatment and site effects was used to examine the treatment difference.
AM/PM is the average of separate morning (AM) and evening (PM) evaluations. T5SS = the sum of the individual scores for nasal congestion/stuffiness, sneezing, rhinorrhea/nasal discharge, nasal pruritis, and ocular pruritis. Each individual symptom/sign was scored from 0 (none) to 3 (severe).
| Arm | Type | Description |
|---|---|---|
| 5-mg Desloratadine tablet | EXPERIMENTAL | - |
| Placebo tablet | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| 5-mg Desloratadine | DRUG | 5-mg Desloratadine tablet, once daily for 12 weeks |
| Placebo tablet | DRUG | Placebo tablet, once daily for 12 weeks |
| Placebo | DRUG | Placebo tablet, once daily for 15 days |
Inclusion Criteria: * For this study, the diagnosis of persistent allergic rhinitis (PER) is not based solely on the current episode of allergic rhinitis (AR). Subjects must have at least a 2 year history of AR consistent with PER (defined as symptoms of allergic rhinitis present more than four day...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 1 | PHASE3 | LY3650150, Standard therapy for INCS |
| Polyrizon Ltd. | PLRZ | 1 | N/A | Undisclosed |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | - | Undisclosed |
5-mg Desloratadine is used for the treatment of allergic rhinitis, including seasonal and perennial forms. It is being developed by Organon & Co. for respiratory conditions. The drug is currently in Phase 3 clinical development and is intended for patients aged 12 years and older.
5-mg Desloratadine is a small molecule antihistamine that works by blocking the effects of histamine, a substance in the body that causes allergic symptoms. It is being studied for its ability to relieve symptoms of allergic rhinitis, such as sneezing, runny nose, and nasal congestion.
5-mg Desloratadine is being developed by Organon & Co., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol OGN. The company is conducting clinical trials to evaluate the drug's safety and efficacy for the treatment of allergic rhinitis.
5-mg Desloratadine is in Phase 3 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The ongoing clinical program includes completed Phase 3 trials that have evaluated the drug in patients with allergic rhinitis.
5-mg Desloratadine has been studied in two completed Phase 3 clinical trials. The first trial, NCT00405964, enrolled 716 patients with persistent allergic rhinitis. The second trial, NCT00406783, enrolled 547 patients with intermittent allergic rhinitis, including seasonal and perennial forms. Both trials were randomized, double-blind, and placebo-controlled.
5-mg Desloratadine is a specific dosage form of desloratadine, an antihistamine medication. The drug is being developed by Organon & Co. for the treatment of allergic rhinitis. It is currently in Phase 3 clinical trials and is not yet approved for use.